These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 27491640)

  • 1. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
    Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
    Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
    Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
    Bexte T; Botezatu L; Miskey C; Gierschek F; Moter A; Wendel P; Reindl LM; Campe J; Villena-Ossa JF; Gebel V; Stein K; Cathomen T; Cremer A; Wels WS; Hudecek M; Ivics Z; Ullrich E
    Mol Ther; 2024 Jul; 32(7):2357-2372. PubMed ID: 38751112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
    Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
    EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
    Singh H; Huls H; Kebriaei P; Cooper LJ
    Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
    Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
    J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
    Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
    Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors.
    Clauss J; Obenaus M; Miskey C; Ivics Z; Izsvák Z; Uckert W; Bunse M
    Hum Gene Ther; 2018 May; 29(5):569-584. PubMed ID: 29562762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated, scaled, transposon-based production of CAR T cells.
    Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
    Ueda T; Kaneko S
    Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
    Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
    Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
    Chicaybam L; Abdo L; Bonamino MH
    Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.